KOREA WHO
-
-
-
CEO of Voronoi
Kim Hyun-tae
From Stockbroker to Biotech CEO: Built a Precision Oncology Firm Worth KRW 2 Trillion
-
Last Updated on May 8, 2025
-
CEO of Voronoi
Life Summary
Kim Hyun-tae(Korean: 김현태) is the CEO of Voronoi.
He leads the company alongside CEO Kim Dae-kwon, who oversees research and development while Kim Hyun-tae is in charge of business operations.
He was born in November 1976.
He graduated from the Department of Business Administration at Seoul National University and completed an MBA program at the Seoul National University Graduate School of Business.
He previously served as head of asset management teams at KB Securities, Hanwha Investment & Securities, and eBEST Investment & Securities. In October 2016, he became the largest shareholder of Voronoi after acquiring a stake in the company. He currently serves as both CEO and chairman of the board.
Kim comes from a background in finance with no prior experience in the biotech industry.
Under his leadership, Voronoi became recognized as a biotech venture firm known for its ability to identify new drug candidates using its proprietary AI platform and vast database. The company has since grown to achieve a market capitalization of KRW 2 trillion (US$ 1.39 billion).
#Voronoi #KimHyuntae #biotech #AIplatform #drugdiscovery #SNUalumni #MBAbusiness #marketcap #pharma #startupCEO
He leads the company alongside CEO Kim Dae-kwon, who oversees research and development while Kim Hyun-tae is in charge of business operations.
He was born in November 1976.
He graduated from the Department of Business Administration at Seoul National University and completed an MBA program at the Seoul National University Graduate School of Business.
He previously served as head of asset management teams at KB Securities, Hanwha Investment & Securities, and eBEST Investment & Securities. In October 2016, he became the largest shareholder of Voronoi after acquiring a stake in the company. He currently serves as both CEO and chairman of the board.
Kim comes from a background in finance with no prior experience in the biotech industry.
Under his leadership, Voronoi became recognized as a biotech venture firm known for its ability to identify new drug candidates using its proprietary AI platform and vast database. The company has since grown to achieve a market capitalization of KRW 2 trillion (US$ 1.39 billion).
#Voronoi #KimHyuntae #biotech #AIplatform #drugdiscovery #SNUalumni #MBAbusiness #marketcap #pharma #startupCEO